[Translation] A randomized, open-label, two-period, two-crossover single-dose bioequivalence study of bicyclol tablets (25 mg) in healthy subjects under fasting/fed conditions

主要目的：在健康男性与女性受试者中于空腹/餐后条件下，评价受试制剂双环醇片（规格：25 mg，生产商：浙江华海药业股份有限公司）和北京协和药厂有限公司生产的参比制剂双环醇片（百赛诺，规格：25 mg）的生物等效性。次要目的：观察受试制剂双环醇片与参比制剂双环醇片（百赛诺）在健康受试者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the test preparation Bicyclol Tablets (Specification: 25 mg, Manufacturer: Zhejiang Huahai Pharmaceutical Co., Ltd.) and the reference preparation Bicyclol Tablets (Bisano, Specification: 25 mg) produced by Beijing Union Pharmaceutical Co., Ltd. in healthy male and female subjects under fasting/postprandial conditions. Secondary objective: To observe the safety of the test preparation Bicyclol Tablets and the reference preparation Bicyclol Tablets (Bisano) in healthy subjects.

Start Date03 Mar 2024

Sponsor / Collaborator

Zhejiang Huahai Pharmaceutical Co., Ltd.

CTR20231453 / RecruitingPhase 4

双环醇片治疗急性药物性肝损伤多中心、随机、双盲、阳性对照Ⅲ期临床试验——延伸性长期观察研究

[Translation] A multicenter, randomized, double-blind, positive-controlled phase III clinical trial of bicyclol tablets in the treatment of acute drug-induced liver injury: an extended long-term observation study

对完成双环醇片治疗急性药物性肝损伤多中心、随机、双盲、阳性对照Ⅲ期临床试验的受试者进行延伸性长期观察研究，考察肝损伤的远期预后。

[Translation]

An extended long-term observation study was conducted on subjects who completed the multicenter, randomized, double-blind, positive-controlled Phase III clinical trial of bicyclol tablets in the treatment of acute drug-induced liver injury to examine the long-term prognosis of liver injury.

Start Date15 Aug 2023

Sponsor / Collaborator

Beijing Union Pharmaceutical Factory

NCT05711459 / RecruitingNot ApplicableIIT

A Prospective and Multicenter Cohort Study of Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.

The clinical trial is designed to evaluate the efficacy of bicyclol for patients with antineoplastic drug-induced liver injury and investigate factors effecting the therapeutic outcome.

Start Date01 May 2022

Sponsor / Collaborator

Tianjin Cancer Institute

100 Clinical Results associated with HSP70 heat-shock proteins x PKC

100 Translational Medicine associated with HSP70 heat-shock proteins x PKC

0 Patents (Medical) associated with HSP70 heat-shock proteins x PKC

Literatures (Medical) associated with HSP70 heat-shock proteins x PKC

01 Oct 2006·Journal of Biological ChemistryQ2 · BIOLOGY

Invariant Leu Preceding Turn Motif Phosphorylation Site Controls the Interaction of Protein Kinase C with Hsp70

Q2 · BIOLOGY

Article

Author: Alexandra C. Newton ; Tianyan Gao

Heat shock proteins play important roles in regulating signal transduction in cells by associating with, and stabilizing, diverse signaling molecules, including protein kinases. Previously, we have shown that heat shock protein Hsp70 associates with protein kinase C (PKC) via an interaction that is triggered by dephosphorylation at the turn phosphorylation motif. Here we have identified an invariant residue in the carboxyl terminus of PKC that mediates the binding to Hsp70. Specifically, we show that Hsp70 binds to Leu (Leu-640) immediately preceding the conserved turn motif autophosphorylation site (Thr-641) in PKC betaII. Co-immunoprecipitation experiments reveal that mutation of Leu-640 to Gly decreases the interaction of Hsp70 with PKC betaII. This weakened interaction between Hsp70 and the mutant PKCs results in accumulation of dephosphorylated PKC in the detergent-insoluble fraction of cells. In addition, the Hsp70-binding mutant is considerably more sensitive to down-regulation compared with WT PKC: disruption of Hsp70 binding leads to accelerated dephosphorylation and enhanced ubiquitination of mutant PKC upon phorbol ester treatment. Last, pulse-chase experiments demonstrate that Hsp70 preferentially binds the species of mature PKC that has become dephosphorylated compared with the newly synthesized protein that has yet to be phosphorylated. Thus, Hsp70 binds a hydrophobic residue preceding the turn motif, protecting PKC from down-regulation and sustaining the signaling lifetime of the kinase.

01 Oct 2004·Journal of Molecular and Cellular CardiologyQ2 · MEDICINE

Regulation of myocardial heat shock protein 70 gene expression following exercise

Q2 · MEDICINE

Article

Author: C.W. James Melling ; Earl G. Noble ; David B. Thorp

Post-exercise induction of myocardial heat shock protein (Hsp70) gene expression involves the activation of the heat shock transcription factor (HSF1). While the exact mechanisms governing the regulation of HSF1 are unclear, activation is believed to occur subsequent to hyperphosphorylation of specific serine residues. As two important serine kinases, protein kinase A (PKA) and protein kinase C (PKC), have been implicated in many phosphorylative events in myocardial cells, we examined the role of these kinases in the activation of Hsp70 gene expression following exercise. In this report, we show that prior administration of a PKA inhibitor, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide ?2HCl (H-89; 0.36 mg/kg), significantly suppressed the elevation in Hsp70 mRNA (P < 0.05) and protein synthesis (P < 0.05) in male Sprague-Dawley rats following a single bout of exercise. In contrast, this post-exercise elevation in Hsp70 mRNA and protein synthesis was not suppressed following the administration of a PKC inhibitor chelerythrine chloride (CHEL; 5 mg/kg) (P < 0.05). Of note, inhibition of PKA did not alter the nuclear localization and binding affinity of HSF1 to the promotor region of the Hsp70 gene. These data indicate that PKA, and not PKC, plays a necessary role in the early exercise-induced regulation of Hsp70 gene expression, downstream of DNA-binding acquisition. However, the current study does not support previous observations regarding major changes in HSF1 phosphorylation and suggests that other PKA-related mechanisms mediate the activation of Hsp70 gene expression following exercise.

01 Sep 1996·European Journal of Biochemistry

Localization and Properties of Kinases in Clathrin‐Coated Vesicles from Zucchini Hypocotyls

Article

Author: Nicole Happel ; David G. Robinson ; Martin Drucker

Five major polypeptides of 70, 50, 47, 19 and 17 kDa and four minor polypeptides (100, 65, 45 and 39 kDa) become phosphorylated when clathrin‐coated vesicles (CCV) from zucchini hypocotyls are incubated in [γ32P]Mg‐ATP. After dissociation with 0.5 M Tris/HCl the CCV coat polypeptides were subjected to gel filtration in order to separate clathrin triskelions from β‐adaptin‐containing fractions. Only the latter bore kinase activities, with phosphorylated polypeptides of 39 kDa in addition to the 50, 19‐kDa and 17‐kDa polypeptides just mentioned. Heparin, an inhibitor of casein kinase II, permitted the phosphorylation of only the 19‐kDa and 17‐kDa polypeptides. Staurosporine, an inhibitor of protein kinase c‐like acitivities, prevented the phosporylation of the 70‐kDa polypeptide. When recombined with the triskelions the β‐adaptin fractions achieved the phosphorylation of the 45‐kDa and 70‐kDa polypeptides. Because of its heat stability and calcium‐binding properties we interpret the 45‐kDa polypeptide as being a clathrin light chain. Antibodies raised against the 70‐kDa group of heat‐shock proteins (Hsp70) recognize a 70‐kDa polypeptide in the β‐adaptin‐containing fractions. Because this polypeptide only phosphorylates in the presence of triskelions we consider it to be the uncoating ATPase, which is known to aggregate upon dissociation of the CCV coat. Our results therefore indicate that zucchini CCV contain a number of phosphorylable polypeptides equivalent to the β, μ and σ adaptins of bovine brain. Just as in bovine brain CCV a casein‐kinase‐II‐like activity is associated with the zucchini CCV 50/47‐kDa polypeptides, further pointing to their identity as plant μ2/μ1 adaptin equivalents.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis